Shao Chang

Shao-Chun Chang has extensive work experience in the pharmaceutical and medical field. Shao-Chun'smost recent position is Chief Medical Officer at Launch Therapeutics, which they began in 2022. Prior to that, they worked at BeiGene as the Senior Vice President and Head of Clinical Development for solid tumors from 2019 to 2022. From 2016 to 2019, Shao-Chun held various roles at AstraZeneca, including Vice President and Global Medicine Lead for Immuno-Oncology. Before that, they worked at Eli Lilly and Company as a Medical Fellow, Senior Medical Advisor, and Medical Advisor from 2006 to 2016. Shao-Chun began their career as an Instructor at Washington University School of Medicine from 2005 to 2006.

Shao-Chun Chang has a Bachelor of Science in Chemistry from Baylor University. Shao-Chun also attended the Washington University School of Medicine in St. Louis and The University of Texas Medical School at Houston, but no specific degree or field of study was mentioned for those institutions.